• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Serina Therapeutics Inc.

    11/14/24 5:09:38 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SER alert in real time by email
    SC 13G/A 1 d8109491_13g-a.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Serina Therapeutics, Inc.1
    (Name of Issuer)

     

     

    Common Stock, par value $0.0001 per share
    (Title of Class of Securities)

     

     

    81751A108
    (CUSIP Number)

     

     

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [_] Rule 13d-1(b)

     

    [X] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

    __________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    1 The Issuer was formerly known as AgeX Therapeutics, Inc. prior to a merger that occurred on March 26, 2024.

     

     
     

     

    CUSIP No 81751A108    

     

         
    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Broadwood Partners, L.P.  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      187,481  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      187,481  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      187,481  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      2.1%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      PN  
           
         
               
     
     

     

    CUSIP No 81751A108    

     

         
    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Broadwood Capital, Inc.  
         

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
       
    3. SEC USE ONLY
       
       
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
       
      New York
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
       
    5. SOLE VOTING POWER
       
      0
       
    6. SHARED VOTING POWER
       
      187,481
       
    7. SOLE DISPOSITIVE POWER
       
      0
       
    8. SHARED DISPOSITIVE POWER
       
      187,481
       
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      187,481
       
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
                                                                                                              [_]
       
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
      2.1%
       
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      IA, CO
     
     

     

     

    CUSIP No 81751A108    

     

         
    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Neal C. Bradsher  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States of America  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      390  
         
    6. SHARED VOTING POWER  
         
      187,481  
         
    7. SOLE DISPOSITIVE POWER  
         
      390  
         
    8. SHARED DISPOSITIVE POWER  
         
      187,481  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      187,871  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      2.1%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      IN, HC  
           
     
     

     

    CUSIP No 81751A108    

     

           
    Item 1. (a). Name of Issuer:  
           
        Serina Therapeutics, Inc.  
           
      (b). Address of Issuer's Principal Executive Offices:  
           
       

    601 Genome Way, Suite 2001

    Huntsville, Alabama 35806

     
           
           
    Item 2. (a). Name of Person Filing:  
           
       

    Broadwood Partners, L.P.

    Broadwood Capital, Inc.

    Neal C. Bradsher

     
           
      (b). Address of Principal Business Office, or if None, Residence:  
           
       

    Broadwood Partners, L.P.

    c/o Broadwood Capital, Inc.

    156 West 56th Street, 3rd Floor

    New York, New York 10019

     

    Broadwood Capital, Inc.

    156 West 56th Street, 3rd Floor

    New York, New York 10019

     

    Neal C. Bradsher

    c/o Broadwood Capital, Inc.

    156 West 56th Street, 3rd Floor

    New York, New York 10019

     
           
      (c) Citizenship:  
           
       

    Broadwood Partners, L.P. – Delaware

    Broadwood Capital, Inc. – New York

    Neal C. Bradsher – United States of America

     
           
      (d).   Title of Class of Securities:  
           
        Common Stock, par value $0.0001 per share  
           
      (e). CUSIP Number:  
           
        81751A108  

     

     
     

     

     


    Item 3.
      If This Statement is filed pursuant to ss.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a
           
      (a) [_] Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).
           
      (b) [_] Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).
           
      (c) [_] Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
           
      (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) [_] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
           
      (f) [_] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
      (g) [_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
      (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
           
      (i) [_]

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

      (j) [_] A non-U.S. institution in accordance with s.240.13d-1(b)(ii)(J); If filing as a non-U.S. institution in accordance with s.240.13d-1(b)(ii)(J), please specify the type of institution: ____
           
      (k)   [_] Group, in accordance with s.240.13d-1(b)(1)(ii)(J).

     

     
    Item 4. Ownership.
     
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
       
      (a)   Amount beneficially owned:
         
       

    Broadwood Partners, L.P. – 187,481

    Broadwood Capital, Inc. – 187,481

    Neal C. Bradsher – 187,871

         
      (b)   Percent of class:
         
       

    Broadwood Partners, L.P. – 2.1%

    Broadwood Capital, Inc. – 2.1%

    Neal C. Bradsher – 2.1%

         
     
     

     

     

      (c)   Number of shares as to which the person has:
         
        (i) Sole power to vote or to direct the vote    
         

     

    Broadwood Partners, L.P. – 0

    Broadwood Capital, Inc. – 0

    Neal C. Bradsher – 390

     

     
        (ii)   Shared power to vote or to direct the vote    
         

     

    Broadwood Partners, L.P. – 187,481

    Broadwood Capital, Inc. – 187,481

    Neal C. Bradsher – 187,481

     

     
        (iii) Sole power to dispose or to direct the disposition of    
         

     

    Broadwood Partners, L.P. – 0

    Broadwood Capital, Inc. – 0

    Neal C. Bradsher – 390

     

     
        (iv)   Shared power to dispose or to direct the disposition of    
         

     

    Broadwood Partners, L.P. – 187,481

    Broadwood Capital, Inc. – 187,481

    Neal C. Bradsher – 187,481

     
                 

     

     
    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].
     
       
       

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
      If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified.  A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
     
      N/A
       
     
     

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

      If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary.  If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
     

     

      N/A
     

     

     

    Item 8. Identification and Classification of Members of the Group.
       
      If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group.  If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
     

     

      N/A
     

     

     

    Item 9. Notice of Dissolution of Group.
       
      Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity.  See Item 5.

     

     

      N/A

     

     

     
    Item 10. Certification.
     
        By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
         

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      November 14, 2024
      (Date)

     

     

     

    BROADWOOD PARTNERS, L.P.*

     

    By: Broadwood Capital, Inc., its general partner

       
      By:  /s/ Neal C. Bradsher
      Neal C. Bradsher
      President
     

     

     

      BROADWOOD CAPITAL, INC.*
       
      By:  /s/ Neal C. Bradsher
      Neal C. Bradsher
      President
       
       
      /s/ Neal C. Bradsher
      NEAL C. BRADSHER*

     

     

     

     

    * This Reporting Person disclaims beneficial ownership in the Common Stock, except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Act, or for any other purpose.

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

     
     

     

    Exhibit A

     

    AGREEMENT

     

    The undersigned agree that this Schedule 13G dated November 14, 2024 relating to the Common Stock, par value $0.0001 per share, of Serina Therapeutics, Inc. shall be filed on behalf of the undersigned.

     

     

    BROADWOOD PARTNERS, L.P.

     

    By: Broadwood Capital, Inc., its general partner

       
      By:  /s/ Neal C. Bradsher
      Neal C. Bradsher
      President
     

     

     

      BROADWOOD CAPITAL, INC.
       
      By:  /s/ Neal C. Bradsher
      Neal C. Bradsher
      President
       
       
      /s/ Neal C. Bradsher
      NEAL C. BRADSHER

     

     

    Get the next $SER alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SER

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SER
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Venkatesan Jay

      4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

      4/10/25 4:03:12 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Bailey Gregory

      4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

      4/10/25 4:02:46 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Ledger Steven A acquired 95,730 shares (SEC Form 4)

      4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

      4/1/25 4:06:08 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SER
    Financials

    Live finance-specific insights

    See more
    • Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

      On track for first patient dosing of SER-252 in Phase 1b clinical trial in advanced Parkinson's disease in Q4 2025Strengthened balance sheet with recent financingAdvancing innovative POZ Platform across multiple therapeutic modalitiesTwo new seasoned biotech leaders added to the Board of Directors HUNTSVILLE, May 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the first quarter ended March 31, 2025, along with recent business highlights. "We are energized by the substantial progress and strengthened foundation

      5/8/25 4:23:00 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

      HUNTSVILLE, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, today announced its financial results for the third quarter ended September 30, 2024, along with key recent updates. Recent Highlights Partnership and Presentations with Enable Injections: Building on its collaboration with Enable Injections, Serina presented a case study at the 14th Annual Injectables Summit in Boston, MA, detailing the combination of Serina's lead candidate, SER-252 (POZ-apomorphine), w

      11/12/24 5:00:00 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SER
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bailey Gregory bought $17,745 worth of shares (3,866 units at $4.59), increasing direct ownership by 6% to 67,243 units (SEC Form 4)

      4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

      12/19/24 4:05:12 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Bailey Gregory bought $6,851 worth of shares (1,137 units at $6.03), increasing direct ownership by 2% to 63,377 units (SEC Form 4)

      4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

      9/24/24 4:30:06 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Bailey Gregory bought $88,257 worth of shares (14,388 units at $6.13), increasing direct ownership by 30% to 62,240 units (SEC Form 4)

      4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

      9/20/24 6:59:29 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SER
    SEC Filings

    See more
    • Serina Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Serina Therapeutics, Inc. (0001708599) (Filer)

      5/22/25 4:40:16 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Serina Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Serina Therapeutics, Inc. (0001708599) (Filer)

      5/8/25 4:12:25 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Serina Therapeutics Inc.

      10-Q - Serina Therapeutics, Inc. (0001708599) (Filer)

      5/8/25 4:10:21 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SER
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors

      - Renowned neuroscience drug developer joins to support strategic development of long-acting CNS therapeutics – HUNTSVILLE, AL, May 22, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing a pipeline of product candidates leveraging its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Stephen (Steve) Brannan, M.D., to its Board of Directors. Dr. Brannan brings more than three decades of experience in neuroscience and neuropsychiatry drug development, with a proven track record of leading clinical programs from early development through regulatory approval and commercialization

      5/22/25 4:50:00 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Serina Therapeutics Makes Grants to New Employees Under Inducement Plan

      HUNTSVILLE, AL, May 14, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, announced that it has made grants of options to purchase an aggregate of 15,000 shares of Serina's common stock to two new non-executive employees on March 20, 2025 (each, an "Option Grant"). Each Option Grant has an exercise price equal to the closing price of Serina's common stock on March 20, 2025. The Option Grants were offered as material inducement to the employees' employment. The Option Grants were appro

      5/14/25 3:15:00 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

      On track for first patient dosing of SER-252 in Phase 1b clinical trial in advanced Parkinson's disease in Q4 2025Strengthened balance sheet with recent financingAdvancing innovative POZ Platform across multiple therapeutic modalitiesTwo new seasoned biotech leaders added to the Board of Directors HUNTSVILLE, May 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the first quarter ended March 31, 2025, along with recent business highlights. "We are energized by the substantial progress and strengthened foundation

      5/8/25 4:23:00 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SER
    Leadership Updates

    Live Leadership Updates

    See more
    • Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors

      - Renowned neuroscience drug developer joins to support strategic development of long-acting CNS therapeutics – HUNTSVILLE, AL, May 22, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing a pipeline of product candidates leveraging its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Stephen (Steve) Brannan, M.D., to its Board of Directors. Dr. Brannan brings more than three decades of experience in neuroscience and neuropsychiatry drug development, with a proven track record of leading clinical programs from early development through regulatory approval and commercialization

      5/22/25 4:50:00 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors

      HUNTSVILLE, AL, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Jay Venkatesan, MD, MBA, to its Board of Directors. Dr. Venkatesan brings deep expertise in biotechnology investment, company building, and strategic growth, having successfully led and advised multiple biopharma companies through pivotal stages of development, including high-profile mergers and acquisitions. Dr. Venkatesan most recently served as Chairman, President, and CEO of Angion Biomedica until its merger with Elicio Therapeutics in 2023. He

      2/12/25 4:15:00 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors

      HUNTSVILLE, AL, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today announced the appointment of Karen J. Wilson to the Board of Directors. "We are excited to welcome Karen to the Board of Directors. Karen's financial expertise and deep understanding of the biotech landscape will play a crucial role in guiding our strategic initiatives and delivering transformative therapies to patients," said Steve Ledger, Serina's Chief Executive Officer. Ms. Wilson brings over three decades of leadership experiences in the life sciences sector. She currently se

      1/14/25 5:25:00 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SER
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Serina Therapeutics Inc.

      SC 13D/A - Serina Therapeutics, Inc. (0001708599) (Subject)

      12/9/24 4:45:59 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Serina Therapeutics Inc.

      SC 13G/A - Serina Therapeutics, Inc. (0001708599) (Subject)

      11/14/24 5:09:38 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Serina Therapeutics Inc.

      SC 13D/A - Serina Therapeutics, Inc. (0001708599) (Subject)

      7/5/24 4:01:13 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care